16848-12-7

Upstream product

• 406479-32-1 6-chloro-9H-(6-O-benzyl-3,4-O-benzylidene-1-deoxy-D-psicofuranosyl)purine 
• 406479-31-0 2-O-acetyl-6-O-benzyl-3,4-O-benzylidene-1-deoxy-D-psicofuranose 
• 406479-30-9 5-O-benzyl-2,3-O-benzylidene-D-ribono-1,4-lactone 
• 406479-33-2 9H-(6-O-benzyl-3,4-O-benzylidene-1-deoxy-β-D-psicofuranosyl)adenine 

Relevant academic research and scientific papers

METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS

The present invention provides pharmaceutical compositions for the treatment of a hepatitis C infection in a host, comprising an antivirally effective amount of a 2'-C-branched nucleoside or a 2'-C-branched ribofuranosyl nucleoside, or pharmaceutically acceptable salts or esters thereof, in combination with one or more other anti-HCV agent. The present invention further provides the use of a 2'-C-branched nucleoside or a 2'-C-branched ribofuranosyl nucleoside, or pharmaceutically acceptable salts or esters thereof, in the manufacture of a medicament for the treatment of a hepatitis C infection in a host.

Ribose-modified nucleosides as ligands for adenosine receptors: Synthesis, conformational analysis, and biological evaluation of 1′-C-Methyl adenosine analogues

1′-C-Methyl analogues of adenosine and selective adenosine A1 receptor agonists, such as N-[(1R)-1-methyl-2-phenylethyl]adenosine ((R)-PIA) and N6-cyclopentyladenosine, were synthesized to further investigate the subdomain that binds